OC-38: EFFECTS OF VIMANG SUPPLEMENTATION IN ANTIRETROVIRAL-NAÏVE HIV/AIDS PATIENTS

J Pharm Pharmacogn Res 3(suppl. 1): S56, 2015

Proceedings of the 4th International Symposium on Pharmacology of Natural Products FAPRONATURA 2015  September 21st-25th, 2015; Cuban Society of Pharmacology. Topes de Collantes, Sancti Spiritus, Cuba.

Oral Communication

OC-38: EFFECTS OF VIMANG SUPPLEMENTATION IN ANTIRETROVIRAL-NAÏVE HIV/AIDS PATIENTS

Gil L1, Martínez G2, González I2, Tarinas A1,  Álvarez A1,  Giuliani A3, Molina R1, Robaina M4, Tápanes R1,  Pérez J1, Guevara M5, Sellés A5.

1Institute of Tropical Medicine “Pedro Kourí” (IPK), Havana, Cuba. E-mail: lgil@ipk.sld.cu
2Institute of Pharmacy and Food, Havana University, Havana Cuba.
3Department of Chemistry and Medical Biochemistry, University of Milan, Italy.
4National Center Coordinating of Clinical Trials, Havana, Cuba.
5Center of Pharmaceutical Chemistry, Havana, Cuba.

 

Introduction: It is previous reported that HIV populations are deficient in antioxidant system and in vitro HIV replication and depletion of CD4+ T lymphocytes are increased with oxidative stress. The general strategy and combination of micronutrient supplementation as a cost-effective strategy for improving oxidative and nutritional status in HIV infection represent an important complementary deal for treatment in the era of high active antiretroviral therapy. This study assessed the effect of antioxidant extract of Mangifera indica (Vimang) on redox indicators and progression markers of disease. Also toxicological safety was evaluated. Methods: Eighty-two HIV-positive patients were randomized in double-blind clinical trial phase 2 to receive supplements of Vimang or placebo, for 6 months. Plasma antioxidants status (TAS), peroxidation potential (PP) glutathione (GSH), malondialdehyde (MDA), plasma total hydroperoxides (TH), superoxide disumutase (SOD), glutathione peroxidase (GPx), percent of DNA fragmentation (%DNA), CD4, CD38, CD95 lymphocytes subsets and hematological, renal and hepatic indexes were measured at baseline and at 6 months. Results: The supplemented group (n=42) had an increase in plasma TAS (p<0.01), GSH (p<0.05) and GPx (p<0.01) and a reduction in PP (p<0.01), MDA (p<0.01), TH (p<0.01), %DNA (p<0.01) and SOD (p<0.01) when compared with placebo group (n=40). There was also a trend towards a reduction in CD95 receptor (mean ± SD changes over 6 month – 6.12 ± 2.30 vs. – 13.47 ± 3.31 % p=0.08. Conclusions: Supplements of Vimang reduce oxidative stress in HIV with a stabilization of CD4+ T lymphocyte relative count. No significant change (p>0.05) was noted related to micronutrient intake, renal, hematological and hepatic indexes. Vimang antioxidant beneficial effect was found without toxically influences in the 6 months period in HIV studied patients. This is worthy of larger clinical trials; especially both in HIV-positive infected persons who cannot afford antiviral therapies and those with them.

Citation Format: Gil L, Martínez G, González I, Tarinas A, Álvarez A, Giuliani A, Molina R, Robaina M, Tápanes R, Pérez J, Guevara M, Sellés A (2015) Effects of Vimang supplementation in antiretroviral-Naïve HIV/AIDS patients. [Abstract]. In: Proceedings of the FAPRONATURA 2015; 2015 Sep 21-25; Topes de Collantes, Sancti Spiritus: CSF. J Pharm Pharmacogn Res 3(Suppl. 1): S56. Abstract nr OC-38.